RxDoctor Payments DataLook up a doctor →

Kennon Mc Collum

Nurse Practitioner · Stockbridge, GANPI 1427036409

Payments from drug & device makers

$363,587in general payments, 2019–2025

Across 812 payments — averaging $447.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$78K
  • Johnson & Johnson$53K
  • Pharmacyclics LLC, An Abbvie Company$52K
  • Incyte Corporation$46K
  • E.r. Squibb & Sons, L.L.C.$28K
  • Coherus Oncology, Inc.$21K
  • plus $85K from 50 others

What the payments were for

  • Consulting fees$37,22510%
  • Speaking & faculty fees$258,35771%
  • Travel & lodging$53,79415%
  • Food & beverage$13,7714%
  • Education$4390%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$363,587 in reported general payments places this provider in the 95th percentile of 3,328 nurse practitioner providers in Georgia.

See all nurse practitioner providers in Georgia

Medicare billing

Part B allowed, 2024
$23,131
Medicare patients
138
Services billed
367

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ImbruvicaIbrutinib34$568,310
IbrancePalbociclib17$272,618
EliquisApixaban38$31,431
XareltoRivaroxaban30$22,797
Dexamethasone28$1,123
Ondansetron Hcl35$1,062
Anastrozole43$786
Entecavir21$408
Gabapentin27$258
Acyclovir12$205
Lidocaine-PrilocaineLidocaine/Prilocaine13$151
Allopurinol19$140
Hydroxyurea11$136
Warfarin Sodium12$75

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Pharmacyclics LLC, An Abbvie CompanyImbruvica$51,510$568,31034 claims
PfizerIbrance, Eliquis$4,009$304,05055 claims
Johnson & JohnsonXarelto$53,034$22,79730 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,328 nurse practitioner providers in Georgia.

Other nurse practitioner in Stockbridge

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →